

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Ruxolitinib for treating non-segmental vitiligo in people 12 years and over [ID3998]

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

At scoping consultation, the following comments were made:

The condition is more noticeable in darker skin tones, but the psychological impact is apparent for all skin tones, along with the risk of sunburn for all skin tones.

There is a risk of depression and anxiety which may be greatest in the Black and minority ethnic populations.

Some quality-of-life measures may discriminate against non-native English speakers

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The committee should consider the cost effectiveness of ruxolitinib across the whole population.

When using quality-of-life tools, healthcare professionals should take into account any physical, psychological, sensory or learning disabilities, or communication difficulties that could affect the responses, and make any adjustments they consider appropriate.

3. Has any change to the draft scope been agreed to highlight potential equality issues?
No.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?
No.

Approved by Associate Director (name): ...Linda Landells.....

Date: 1 June 2023